| 000 | 01153 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513035747.0 | ||
| 264 | 0 | _c19951006 | |
| 008 | 199510s 0 0 eng d | ||
| 022 | _a0002-8703 | ||
| 024 | 7 |
_a10.1016/0002-8703(95)90305-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTcheng, J E | |
| 245 | 0 | 0 |
_aEnhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. _h[electronic resource] |
| 260 |
_bAmerican heart journal _cSep 1995 |
||
| 300 |
_a673-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadverse effects |
| 650 | 0 | 4 |
_aPeptides _xadverse effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aSafety |
| 773 | 0 |
_tAmerican heart journal _gvol. 130 _gno. 3 Pt 2 _gp. 673-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0002-8703(95)90305-4 _zAvailable from publisher's website |
| 999 |
_c7667646 _d7667646 |
||